Summary：Revolutionary Sleep Apnea Treatment Wins Prestigious Prix Galien UK 2026 AwardMont-Saint-Guibert, Be

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Revolutionary Sleep Apnea Treatment Wins Prestigious Prix Galien UK 2026 Award

Mont-Saint-Guibert, Belgium – June 15, 2026, 10:05 pm CET / 04:05 pm ET – Nyxoah’s groundbreaking Genio® system for the treatment of obstructive sleep apnea (OSA) has been awarded the esteemed Prix Galien UK 2026 Award in the category of Best Medical Technology. This prestigious accolade recognizes the company's innovative approach to addressing a pressing healthcare challenge affecting millions worldwide.

The Genio® system represents a significant breakthrough in the management of OSA, a condition characterized by repeated interruptions in breathing during sleep, resulting in fragmented rest and associated comorbidities. By utilizing a novel neurostimulation therapy, Genio® offers a minimally invasive, patient-centric solution that has demonstrated substantial efficacy in clinical trials. The therapy involves the implantation of a small device that selectively stimulates the hypoglossal nerve, promoting the patency of the upper airway and thereby reducing apneic events.

The Prix Galien UK Award is a testament to Nyxoah's commitment to advancing medical technology and improving patient outcomes. The recognition comes at a time when the global sleep apnea market is witnessing a paradigm shift towards more effective and less invasive treatments. Industry analysts forecast a compound annual growth rate (CAGR) of 12% for the sleep apnea devices market through 2030, driven by increasing awareness, technological innovation, and an aging population.

The success of Genio® not only underscores the potential for neurostimulation therapies to redefine the treatment landscape for OSA but also highlights the importance of continued investment in medical research and development. As healthcare systems worldwide grapple with the burden of sleep disorders, innovative solutions like Genio® are poised to play a pivotal role in enhancing the quality of life for patients and reducing healthcare costs associated with untreated OSA.

Looking ahead, Nyxoah is expected to leverage the momentum generated by the Prix Galien UK Award to further expand the adoption of Genio® across key markets. With its pioneering technology and a growing body of clinical evidence supporting its efficacy, Genio® is set to remain at the forefront of sleep apnea treatment innovation.

In conclusion, Nyxoah's receipt of the Prix Galien UK 2026 Award for its Genio® system is a landmark recognition of the company's innovative contribution to the field of sleep medicine. As the global healthcare community continues to evolve, the impact of this technology is likely to be felt for years to come, offering new hope to patients and clinicians alike in the management of obstructive sleep apnea.